SG11202010387QA - Starting dose of pth conjugates - Google Patents
Starting dose of pth conjugatesInfo
- Publication number
- SG11202010387QA SG11202010387QA SG11202010387QA SG11202010387QA SG11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA
- Authority
- SG
- Singapore
- Prior art keywords
- starting dose
- pth
- conjugates
- pth conjugates
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18173155 | 2018-05-18 | ||
| PCT/EP2019/062773 WO2019219896A1 (en) | 2018-05-18 | 2019-05-17 | Starting dose of pth conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010387QA true SG11202010387QA (en) | 2020-11-27 |
Family
ID=62217789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010387QA SG11202010387QA (en) | 2018-05-18 | 2019-05-17 | Starting dose of pth conjugates |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210196801A1 (en) |
| EP (1) | EP3793587A1 (en) |
| JP (1) | JP2021524445A (en) |
| KR (1) | KR20210013584A (en) |
| CN (1) | CN112334152A (en) |
| AU (1) | AU2019270464A1 (en) |
| BR (1) | BR112020022306A2 (en) |
| CA (1) | CA3099620A1 (en) |
| MX (1) | MX2020012179A (en) |
| SG (1) | SG11202010387QA (en) |
| WO (1) | WO2019219896A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45277A (en) * | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases As | PRE-MEDICINES FOR PTH |
| HRP20231079T1 (en) | 2016-09-29 | 2023-12-22 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
| HRP20230383T1 (en) | 2016-09-29 | 2023-07-07 | Ascendis Pharma Bone Diseases A/S | Pth compounds with low peak-to-trough ratios |
| CN115003320A (en) * | 2020-01-13 | 2022-09-02 | 阿森迪斯药物骨疾病股份有限公司 | Treatment of hypoparathyroidism |
| WO2022064035A1 (en) * | 2020-09-28 | 2022-03-31 | Ascendis Pharma Bone Diseases A/S | Improvement of physical and mental well-being of patients with hypoparathyroidism |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| PT1620118E (en) | 2003-04-08 | 2014-10-16 | Yeda Res & Dev | Reversible pegylated drugs |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| US20070203058A1 (en) | 2003-09-19 | 2007-08-30 | Novo Nordisk A/S | Novel Glp-1 Derivatives |
| BR122019000248B8 (en) | 2004-03-23 | 2021-07-27 | Complex Biosystems Gmbh | polymeric cascade prodrug binder reagent |
| CN101151048A (en) * | 2004-05-10 | 2008-03-26 | 纳斯泰克制药公司 | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| CA2662978A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| SI2173890T1 (en) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biological active proteins having increased in vivo and/or vitro stability |
| EP2175878A4 (en) | 2007-07-11 | 2014-12-03 | Belrose Pharma Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| LT2237799T (en) | 2008-02-01 | 2019-07-25 | Ascendis Pharma A/S | Prodrug comprising a self-cleavable linker |
| CA2723263A1 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| LT2393828T (en) | 2009-02-03 | 2017-01-25 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
| US9173953B2 (en) | 2009-07-31 | 2015-11-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
| WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| JP5964815B2 (en) | 2010-05-05 | 2016-08-03 | プロリンクス リミテッド ライアビリティ カンパニー | Controlled release drug from solid carrier |
| CN103025165B (en) | 2010-05-05 | 2016-06-08 | 普罗林科斯有限责任公司 | From the controlled release of macromolecular conjugates |
| EA024755B1 (en) | 2010-05-21 | 2016-10-31 | ИксЭль-ПРОТЕИН ГМБХ | Biosynthetic proline/alanine random coil polypeptides and their uses |
| US8989456B2 (en) | 2010-06-30 | 2015-03-24 | Nec Solution Innovators, Ltd. | Attribute determining method, attribute determining apparatus, program, recording medium, and attribute determining system |
| AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| JP6092867B2 (en) | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー／エス | Carrier-linked treprostinil prodrug |
| WO2013024053A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| AU2012296950B2 (en) | 2011-08-12 | 2016-09-22 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| US20150087688A1 (en) | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| CN104955472A (en) | 2012-10-17 | 2015-09-30 | 诺和诺德保健股份有限公司 | Fatty acid acylated amino acids for growth hormone delivery |
| EP3193941A1 (en) | 2014-08-06 | 2017-07-26 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| MA45277A (en) | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases As | PRE-MEDICINES FOR PTH |
| HRP20231079T1 (en) * | 2016-09-29 | 2023-12-22 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
| CA3037444A1 (en) * | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
-
2019
- 2019-05-17 JP JP2020564461A patent/JP2021524445A/en active Pending
- 2019-05-17 MX MX2020012179A patent/MX2020012179A/en unknown
- 2019-05-17 AU AU2019270464A patent/AU2019270464A1/en active Pending
- 2019-05-17 EP EP19724825.5A patent/EP3793587A1/en active Pending
- 2019-05-17 CA CA3099620A patent/CA3099620A1/en active Pending
- 2019-05-17 US US17/055,695 patent/US20210196801A1/en active Pending
- 2019-05-17 CN CN201980041822.5A patent/CN112334152A/en active Pending
- 2019-05-17 BR BR112020022306-9A patent/BR112020022306A2/en unknown
- 2019-05-17 WO PCT/EP2019/062773 patent/WO2019219896A1/en active Application Filing
- 2019-05-17 SG SG11202010387QA patent/SG11202010387QA/en unknown
- 2019-05-17 KR KR1020207036187A patent/KR20210013584A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3793587A1 (en) | 2021-03-24 |
| WO2019219896A1 (en) | 2019-11-21 |
| MX2020012179A (en) | 2021-01-29 |
| CA3099620A1 (en) | 2019-11-21 |
| JP2021524445A (en) | 2021-09-13 |
| KR20210013584A (en) | 2021-02-04 |
| BR112020022306A2 (en) | 2021-02-23 |
| AU2019270464A1 (en) | 2020-11-19 |
| US20210196801A1 (en) | 2021-07-01 |
| CN112334152A (en) | 2021-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| SG11202010387QA (en) | Starting dose of pth conjugates | |
| GB201804255D0 (en) | Macrophage-based therapy | |
| GB201615442D0 (en) | Dose setting mechanism | |
| IL282330A (en) | Therapeutic compounds | |
| IL284047A (en) | Combination hbv therapy | |
| GB201819853D0 (en) | Therapy | |
| GB201716942D0 (en) | Therapeutic compounds | |
| SG11202008718UA (en) | Combination therapy for cardiovascular diseases | |
| GB201615439D0 (en) | Dose setting mechanism | |
| IL276996A (en) | Inhaler | |
| IL269169A (en) | Novel dosage form | |
| GB201808150D0 (en) | Therapeutic compounds | |
| ZA201907286B (en) | A pharmaceutical combination for the treatment of a cancer | |
| PL3630754T3 (en) | Isoindoline-acetylene compounds for the treatment of cancer | |
| EP3801713C0 (en) | Inhaler | |
| GB201820895D0 (en) | Therapy | |
| GB2569410B (en) | Booster burner | |
| GB201817385D0 (en) | Therapy | |
| GB201814038D0 (en) | Ilven therapy | |
| GB201712884D0 (en) | Novel therapeutic compounds | |
| GB201809828D0 (en) | Combined hormal therapy | |
| GB201712394D0 (en) | Therapeutic compounds | |
| GB201712390D0 (en) | Therapeutic compounds | |
| GB201712395D0 (en) | Therapeutic compounds |